ALPHA-METHYL-SUBSTITUTED DIAZABICYCLO [4.3.1] DECANE DERIVATES FOR TREATMENT OF PSYCHIATRIC DISORDERS

The present invention relates to alpha-methyl substituted diazabicyclo-[4.3.1]-decane derivatives and stereo-isomeric forms, solvates, hydrates and/or pharmaceutically acceptable salts of these compounds as well as pharmaceutical compositions containing at least one of these alpha-methyl bicyclic aza-amides derivatives together with pharmaceutically acceptable carrier, excipient and/or diluents. Said alpha-methyl substituted diazabicyclo-[4.3.1]-decane derivatives have been identified as especially potent inhibitors of the FK506 binding proteins (FKBPs), especially FKBP12, FKBP12.6, FKBP51 and FKBP52 or bacterial homologs like LpMIP, CpMIP or CtMIP, to and are useful for the psychiatric, metabolic, infective, neurological and hematologial disorders as well as pain diseases and cancers.